Inotiv (NASDAQ:NOTV) Announces Quarterly Earnings Results

Inotiv (NASDAQ:NOTV) announced its earnings results on Wednesday. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10), Zacks reports. Inotiv had a negative net margin of 22.10% and a negative return on equity of 15.86%.

Inotiv Stock Performance

Shares of NOTV stock traded down $0.31 during midday trading on Wednesday, hitting $4.18. The company had a trading volume of 813,127 shares, compared to its average volume of 622,475. The stock has a market cap of $108.72 million, a price-to-earnings ratio of -1.00 and a beta of 3.58. The company has a debt-to-equity ratio of 2.29, a current ratio of 1.37 and a quick ratio of 1.22. The company’s 50 day simple moving average is $4.41 and its 200 day simple moving average is $2.79. Inotiv has a 52-week low of $1.23 and a 52-week high of $11.42.

Insider Activity at Inotiv

In other news, Director Nigel Brown purchased 7,500 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was acquired at an average price of $4.26 per share, for a total transaction of $31,950.00. Following the completion of the transaction, the director now directly owns 65,537 shares in the company, valued at $279,187.62. This represents a 12.92 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Michael J. Harrington purchased 10,000 shares of Inotiv stock in a transaction on Friday, December 6th. The stock was acquired at an average cost of $3.98 per share, for a total transaction of $39,800.00. Following the acquisition, the director now directly owns 37,500 shares of the company’s stock, valued at approximately $149,250. This represents a 36.36 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have bought 71,029 shares of company stock worth $314,248 and have sold 26,872 shares worth $112,854. 7.80% of the stock is currently owned by insiders.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.